Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × Neoadjuvant Therapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 58 Colorectal Neoplasms 31 Rectal Neoplasms 30 Carcinoma, Non-Small-Cell Lung 21 Esophageal Neoplasms 20 Esophageal Squamous Cell Carcinoma 19 Pancreatic Neoplasms 14 Neoplasms 13 Lung Neoplasms 11 Adenocarcinoma Of Esophagus 11 Stomach Neoplasms 10 Carcinoma, Hepatocellular 10 Ovarian Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Prostatic Neoplasms 8 Urinary Bladder Neoplasms 7 Sarcoma 7 Neoplasm Metastasis 7 Head and Neck Neoplasms 7 Uterine Cervical Neoplasms 6 Colonic Neoplasms 6 Recurrence 5 Osteosarcoma 5 Multiple Myeloma 5 Fallopian Tube Neoplasms 5 Peritoneal Neoplasms 4 Nasopharyngeal Carcinoma 4 Locally Advanced Rectal Cancer 4 Inflammatory Breast Neoplasms 4 Cholangiocarcinoma 4

Interventions

osimertinib 7 Pemetrexed 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡